Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mai 2024 15h15 HE | Source: Robbins LLP

Stockholder Alert: Robbins LLP Reminds BLUE Investors of Upcoming May 28, 2024 Lead Plaintiff Deadline in the Bluebird Bio, Inc. Class Action

Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
26 avr. 2024 16h45 HE | Source: Robbins LLP

Robbins LLP Reminds Investors of Bluebird Bio, Inc. to Contact the Law Firm for Information About the Class Action Against BLUE

Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
17 avr. 2024 19h42 HE | Source: Robbins LLP

BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline

Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
09 avr. 2024 14h37 HE | Source: Robbins LLP

bluebird bio, Inc. (BLUE) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc.

Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
30 mars 2024 01h44 HE | Source: Robbins LLP

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. (BLUE)

Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug